HEXO Strengthens Commitment to Research and Innovation, Appointing Chief Innovation Officer
GATINEAU, Quebec, Jan. 15, 2019 (GLOBE NEWSWIRE) — HEXO Corp. (“HEXO” or the “Company”) (TSX:HEXO) is strengthening its commitment towards research and innovation by appointing Veronique Hamel as its Chief Innovation Officer. With global experience in new product development Ms. Hamel is well positioned to develop research strategy and oversee HEXO Corp’s research and innovation pipeline.
“I am pleased to welcome Veronique to our leadership team,” said HEXO’s CEO and co-founder, Sebastien St-Louis. “Veronique has a track record for building and helping shape high growth and consumer-centric organizations through trusted and award-winning innovations. She brings a strong business acumen to the process of innovation as well as a passion for break-throughs and industry firsts.”
Throughout her career spanning over 25 years, Veronique Hamel has developed expertise in innovation through leadership roles in research and development, new product development, marketing, and business development for global consumer goods and pharmaceutical companies in Europe, the U.S. and Canada.
Most recently, Veronique has built strong, innovative teams in Canada at Church & Dwight Canada, Bausch & Lomb and Bausch Health Companies Inc.
“I am proud to join the competent team at HEXO,” said Veronique Hamel. “HEXO has already shown extraordinary commitment to quality and innovation and has been recognized for that. I am thrilled to be on board to expand the Company’s innovation footprint and bring exciting, new and trusted solutions to consumers.”
Veronique Hamel is a graduate from EDHEC Business school in France.
About HEXO Corp.
HEXO Corp creates and distributes award-winning, innovative, easy-to-use products to serve the Canadian cannabis market. One of the country’s lowest-cost producers, HEXO currently operates with over 310,000 sq. ft. of production capacity with construction on another 1,000,000 sq. ft. expansion set to be complete by year end. HEXO serves the adult-use market under the HEXO brand, while continuing to serve its medical cannabis clients through the well-known Hydropothecary brand. For more information please visit hexocorp.com.
This press release may contain forward-looking information that is based on certain assumptions and involves known and unknown risks and uncertainties and other factors that could cause actual events to differ materially from current assumptions and expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s Annual Information Form and continuous disclosure filings, which are available on SEDAR’s website at www.sedar.com. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
A photo accompanying this announcement is available at: